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The purpose of this study is to determine the incidence, clinical characteristics and risk factors of postradiation
pelvic insufficiency fracture (PIF) in women with uterine cervical cancer. We reviewed the medical records of
126 patients who received definitive radiotherapy (RT) for uterine cervical cancer between 2003 and 2009 at
our institution. Among them, 99 patients who underwent at least one computed tomography (CT) or magnetic
resonance imaging of the pelvis during their follow-up at more than 6 months were included in this analysis.
The relationship between the incidence of PIF and several patient- and treatment-related factors was analyzed.
The median follow-up period was 21 months. Of the 126 patients, 33 (with a total of 50 lesions) were diag-
nosed with PIF. The 2-year cumulative incidence was 32%. Univariate analysis showed that age ≥70 years
(P= 0.0010), postmenopausal state (P = 0.0013), and lower CT density of bone and bone marrow (P= 0.020)
significantly related to PIF. In a multivariate analysis, of the 59 patients whose CT densities were evaluable,
lower CT density was the only significant factor associated with PIF (P = 0.0026). In conclusion, postradiation
PIFs were detected in a considerable number of patients after definitive RT for cervical cancer. Predisposing
factors were older age, postmenopausal state, and decreased density of bone and bone marrow on CT.
Keywords: adverse event; CT density; pelvic insufficiency fracture; radiotherapy; uterine cervical cancer
INTRODUCTION
Radiotherapy (RT) has been considered an essential method
for the treatment of uterine cervical cancer. Survivorship has
improved since the introduction of platinum-based chemora-
diotherapy, and the late effects of the treatment have drawn
more attention. Although postradiation pelvic insufficiency
fracture (PIF) was considered a relatively rare adverse event
after pelvic irradiation, several clinical investigations have
shown that postradiation PIF is more common than previously
thought [1–8]. Injury and occlusion of the microvasculature of
mature bone and stasis of osteoclasts and osteoblasts are
thought to be major mechanisms of RT-induced insufficiency
fracture [9]. Recent studies suggest that older age, postmeno-
pausal status, lower body weight or body mass index (BMI),
RT intensity (the larger volume and dose irradiated, and the
use of concurrent chemotherapy), and higher numbers of
deliveries are risk factors for RT-induced PIF [1–3, 7]. In the
general population, postmenopausal state, high-dose cortico-
steroid use, rheumatoid arthritis, diabetes mellitus, heparin
use, low body weight, and smoking history are known to be
associated with pelvic insufficiency fracture [10].
To our knowledge, no studies have addressed the correl-
ation between postradiation insufficiency fracture and the
quantitative assessment of osteoporosis. We retrospectively
evaluate the incidence of PIF at our institution and analyze
the associated risk factors, including the quantitative assess-
ment of osteoporosis.
MATERIALS ANDMETHODS
Study population
The RT records and the medical charts of 126 patients with
cervical cancer who received definitive RT consisting of
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external beam (EBRT) and high-dose-rate intracavitary
brachytherapy (HDR-ICBT) at our institution between
January 2003 and December 2009 were reviewed. We
obtained written consents from all patients in this study
regarding the use of their medical records for the purpose of
clinical studies. Patients who received postoperative adjuvant
RT were not included. Of the 126 patients, 99 who under-
went at least one pelvic computed tomography (CT) or mag-
netic resonance imaging (MRI) during their follow-up at > 6
months after the initiation of RT were included in this study.
Pretreatment CT images for RT planning were available for
all patients for comparison. Patient characteristics are
described in Table 1.
Treatment
All patients received both EBRT and HDR-ICBT. EBRT
was delivered to the whole pelvic (WP) field followed by the
same WP field with central shielding. EBRT was prescribed
with a median prescribed dose of 50.4 Gy (range, 45.0–50.4
Gy) at 1.8 Gy per fraction, five days per week, using 10-MV
photons. A 4-field box technique was used in 78 patients
(79%) and an anteroposterior/posteroanterior (AP/PA)
field was used in 21 patients (21%). In general, we used a
4-field box technique unless the patient had undergone
hip-replacement surgery, had severe osteoarthritis in the hip
joint, required irradiation to the inguinal region, or had a thin
body shape in which the distance between the anterior and
posterior abdominal wall was less than 20 cm. Central shield-
ing was used in 97 patients after the WP RT. The median pre-
scribed dose for central shielding field was 14.4 Gy (range,
5.4–34.2 Gy). Boost EBRT was added to metastatic lymph
nodes in 19 cases with 4–8 Gy (median 6 Gy) at 1.8–2.0 Gy
per fraction. All EBRT was planned with the CT-based
treatment-planning system (FOCUS 9200 ver. 3.2.1, XiO
ver. 4.20 – ver.4.60, CMS/Elekta, Stockholm, Sweden).
WP fields were designed as described below. The superior
border was set at either the L4–5 intervertebral level or the
aortic bifurcation, depending on which was located more su-
periorly. In patients with positive para-aortic nodes, the RT
fields were extended up to levels in which the involved
lymph nodes were adequately included. The inferior border
was at the bottom (inferior margin) of the obturator foramen,
or 2–3 cm below the lowest extent of the cervical or vaginal
involvement. The lateral border was at 1.5–2 cm lateral to the
external margin of the small pelvis. The anterior border was
at 0–1 cm anterior to the pubic symphysis, and the posterior
border was adjusted to the posterior edge of the sacrum.
Every field was confirmed to include the lymphatic area con-
toured on CT.
HDR-ICBT was delivered to all patients with the Fletcher-
Williamson applicator (tandem and ovoid) system or tandem
and segmented cylinder applicator. We used a microSelectron
HDR and PLATO (Nucletron/Elekta) as a radioactive source
delivery and a treatment-planning system, respectively. The
median total dose of HDR-ICBT was 22 Gy (range, 6–30
Gy), 5–6 Gy per fraction to point A, weekly. The median
total dose prescribed to point A (WP EBRT and HDR-ICBT)
normalized to biological effective dose (BED) at α/β = 3 and
α/β = 10 were 120.2 Gy (range, 84.2–139.0 Gy) and 74.5 Gy
(range, 36.3–84.1 Gy), respectively.
Chemotherapy was administered to 68 patients (concurrent-
ly and sequentially in 67 patients and 1 patient, respectively).
Therapeutic regimens of concurrent chemotherapy consisted
of weekly nedaplatin (cis-diammine-glycoplatinum) at 30 mg/
m2 (58 of 67, 87%), weekly cisplatin at 30–40 mg/m2 (7 of
67, 10%), and irinotecan at 40 mg/m2 (2 of 67, 3%).
Nedaplatin, a derivative of cisplatin with similar antitumor
Table 1. Patient characteristics
Characteristics
Median age (range) 68 (31–95) years
Median BMI (range) 21.4 (15.8–32.8)
Menopausal status
premenopausal 14
postmenopausal 85
Smoking status
current/past 21
never 73
unknown 5
Past medical history
diabetes mellitus 14
rheumatoid arthritis 5
Stage (FIGO)
IB 5
IIA 3
IIB 26
IIIA 4
IIIB 47
IVA 14
Histopathology
squamous cell carcinoma 86
adenocarcinoma 7
adenosquamous cell carcinoma 2
poorly differentiated carcinoma 2
neuroendocrine and squamous cell
carcinoma
1
unknown 1
FIGO = International Federation of Gynecology and
Obstetrics.
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activity but less renal and gastrointestinal toxicity, is common-
ly used in Japan. Neoadjuvant and adjuvant chemotherapy
were administered in eight and three patients, respectively.
Follow-up and diagnostic criteria of PIF
For follow-up, patients visits were scheduled at least once a
month until 6 months, every 2 months from 6–12 months,
every 3 months from 1–5 years, then once a year until 10
years after completion of the treatment. As to a follow-up
imaging study, abdominal CT and/or pelvic MRI were per-
formed once at 1–3 months initially, then every 6 months
until two years, and, generally, once a year after that. We
also planned additional imaging study as needed at times of
suspicion of recurrent disease or patient symptoms. Post-
treatment CTs/MRIs were performed a median of 3 times
(range, 1–14 times) during the median clinical follow-up
period of 25 months (range, 9–89 months). The median time
from the start of RT to the latest imaging study was 21
months (range, 6–85 months).
All imaging studies were reviewed separately by a diag-
nostic radiologist and a radiation oncologist (KM and HU).
We defined the diagnostic criteria of insufficiency fracture as
a bony lesion with an apparent fracture line, with or without
sclerotic change detected by CT and/or MRI, within the irra-
diated field. Traumatic or metastatic lesions were excluded
by history, clinical course, and radiological appearance.
A bone marrow change of only sclerosis or edema without
cortical disruption was not defined as insufficiency fracture.
Osteonecrosis of the hip was counted as insufficiency frac-
ture. Fracture sites were categorized into six subgroups in-
cluding the spinal column, sacrum, sacroiliac joint, ilium,
pubis, and femoral head. Some cases had multiple fracture
lines, mainly on the sacrum and one or two fracture lines in-
volving the sacroiliac joint; those cases were categorized as
sacral fracture. Discordant image interpretations for the two
readers were solved by discussion and careful reviewing. We
used a uniform method for all patients, diagnosing PIF only
when a fracture line was confirmed on CT and/or MRI.
A fracture line showed as a sharp, linear, low-density area on
CT, and a low-signal-intensity area on a T1-weighted image.
Measurement of bone and bone marrow CT density
We measured the pretreatment CT density (in Hounsfield
Unit [HU]) of 59 consecutive patients as obtained through a
specific imaging viewer (Synapse, FUJIFILM Medical Co.,
Ltd, Tokyo, Japan). The 59 patients’ imaging data that is
acquired in 2006 and thereafter were obtainable through the
imaging viewer (Synapse) with the function of CT densitom-
etry. However the other 40 patients’ imaging data, acquired
before 2006, were not obtainable through the imaging
viewer. To reduce mis-estimation, we selected seven different
sites of bone marrow within the general irradiation field. We
selected three different transaxial images showing visually
the lowest bone-marrow density on bone windows in the
right and left side of the sacrum. A 1-cm diameter circle
region of interest was utilized to measure the CT density of
bone and bone marrow on each of the six slices. We calcu-
lated the mean value for the three on each side. We selected
the transaxial image that appeared the most homogenous for
the L5 vertebra, and measured the vertebral bone and bone-
marrow density. Each of the three values (L5 vertebra, right
and left sacrum) and the mean of the three values were used
for analysis. A representative case is shown on Fig 1.
Dose-volume analysis
Dosimetric analyses of EBRT were performed on 70 con-
secutive patients whose EBRT planning data were available.
We contoured eight segments of pelvic bone including the
fifth lumbar vertebra, sacrum, right and left sacroiliac joints,
ilium and pubis on the treatment-planning CT. Dosimetric
Fig. 1. (A) Transaxial image of an RT-planning CT of a
representative case. Area of visually lowest density of bone marrow
in the right and left sacrum coincided with each other in this case.
CT densitometry shows −87 and −97 HU on the right and left sacral
bone marrow, respectively. (B) Transaxial image of a RT-planning
CT of the same case as Fig. 1A. L5 lumbar vertebra shows the most
homogenous bone marrow density on this slice. CT densitometry
shows 72 HU on L5 lumbar vertebra.
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parameters including V20, 30, 40, 50 and the mean dose of
each segment were calculated, and the relationship to the in-
cidence of PIF was evaluated.
Endpoints and statistical data analysis
We defined the onset of PIF as the date of detection on
imaging study. In patients with multiple injuries detected
separately, the date of the first event onset was recorded. The
date of the latest imaging study was counted for censoring.
The cumulative incidence rate of PIF was calculated by the
Kaplan-Meier method. The relationship between the inci-
dence of PIF and the potential risk factors (age, menopausal
status, type II diabetes mellitus, rheumatoid arthritis, RT
technique, RT dose, and chemotherapy use) were analyzed
by the log-rank test (univariate analysis). Multivariate ana-
lysis using the Cox proportional hazard model was carried
out on those factors with P < 0.1 in the univariate analysis.
The patient population whose CT density was not available
was excluded from multivariate analysis. P-values less than
0.05 were considered statistically significant. Correlation
between CT density of bone and bone marrow, and postme-
nopausal status and age were analyzed by t-test. We also ana-
lyzed the relationship between age and disease stage, and
chemotherapy use by t-test. Statistical data analyses were
performed using JMP 8 (SAS institute, Cary, NC, USA).
RESULTS
Of the 99 patients, 33 (with 50 lesions) were diagnosed with
PIF within the irradiated field. The time interval between RT
initiation and PIF detection was 2–46 months (median, 14
months). The 2- and 5-year cumulative incidences of overall
PIF were 32% and 63%, respectively (Fig. 2A). Lumbar or
pelvic pain which was considered to be related to PIF devel-
oped in 20 patients (61%). Among these, 16 patients
achieved pain relief with nonsteroidal anti-inflammatory
drugs, but three required narcotic analgesics. One patient
with femoral head necrosis underwent hip replacement
surgery because of intolerable pain with conservative
therapy. The onset of symptoms varied from 1–60 months
(median, 11 months). The 2- and 5-year cumulative inci-
dences of symptomatic PIF were 21% and 33%, respectively
(Fig. 2B). The distribution of PIF in the patients was as
follows: lumbar spinal vertebra in 14 (28%), sacrum in 14
(28%), pubis in 13 (26%), sacroiliac joint in 4 (8%), ilium in
3 (6%), and femoral head in 2 (4%) (Fig. 3). Most pubic frac-
tures were seen adjacent to the symphysis pubis.
The relationship between the occurrence of PIF and
clinical- and treatment-related factors are summarized in
Table 2A. Univariate analysis revealed age ≥70 years (2-year
incidence 47% vs 16%, P = 0.0010), postmenopausal status
(2-year incidence 36% vs 0%, P = 0.0013), and mean CT
density < 35 HU (2-year incidence 46% vs 24%, P = 0.020)
as statistically significant predisposing factors for developing
PIF. CT density measured at the three sites independently
showed the relationship with PIF (Table 2B). Patients who
did not receive chemotherapy showed a higher incidence of
PIF than those who did. There were significant correlations
between CT density, postmenopausal status and age. The
mean CT density of pre- and postmenopausal patients was
37 and 105 HU, respectively (P = 0.0008). The mean age of
CT density ≤ 35 HU and > 35 HU were 75 and 60 years, re-
spectively (P≤ 0.0001). Younger patients were prone to more
advanced disease in this study. Comparing Stage I–II with
III–IV, the mean age of each group was 70 and 65 years, re-
spectively (P= 0.09). In addition, younger patients were
more likely to receive chemotherapy. The mean age of
patients who received chemotherapy and who did not receive
was 61 and 77 years, respectively (P < 0.0001). Although
some factors may be confounding in part, multivariate ana-
lysis revealed that lower CT density was the only significant
predisposing risk factor (Table 3). As the CT densities were
Fig. 2. (A) Cumulative incidence of overall PIF after pelvic radiotherapy for uterine cervical cancer. The 2- and 5-year
cumulative incidences of overall PIF were 32% and 63%, respectively. (B) Cumulative incidence of symptomatic PIF. The 2- and
5-year cumulative incidences were 21% and 33%, respectively.
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evaluable only in 59 of the 99 cases, we performed multi-
variate analysis on the whole cohort (n = 99) without the CT
density factor. We found no significant difference for age
(P = 0.07), menopausal state (P = 0.09) or the use of chemo-
therapy (P = 0.99).
CT density obtained from L5 and the right and left sacrum
ranged from 25 to 302, −108 to 55, and −110 to 53 (median,
129, −49, and − 55) HU, respectively. The mean of the
three values ranged from −42.5 to 177.5 (median, 35.5) HU.
A representative case of sacral PIF is shown in Fig. 4. An
80 year-old woman with International Federation of
Gynecology and Obstetrics (FIGO) stage IIIB uterine cer-
vical cancer (the same case as presented in Fig. 1) treated
with definitive RT developed pelvic pain 12 months after the
start of RT. A transaxial image of follow-up CT shows mul-
tiple fracture lines in the sacrum (Fig. 4).
We performed dosimetric analyses of EBRT on 70
patients (Table 4). Although not statistically significant, a
lower dose of EBRT showed a higher fracture rate trend in
the left pubis. The 2-year incidence of PIF in groups with
EBRT doses of >43 Gy and ≤43 Gy were 7% vs 14%, re-
spectively (p = 0.26). On the other hand, patients who
received a higher total dose of HDR-ICBT were prone to left
pubic insufficiency fracture in the group of 70 patients in
which EBRT dose-volume correlation was analyzed. The
2-year incidences of PIF in the groups of HDR-ICBT
dose >22 Gy and ≤22 Gy were 16% vs 7%, respectively
(P = 0.16). However, a statistically significant correlation
was not observed between dose-volume histogram (DVH)
parameters and the incidence of PIF.
DISCUSSION
The 2-year cumulative incidence rate of PIF after radiother-
apy was 32% in the current study. Estimated predisposing
risk factors were older age, postmenopausal status, and
decreased CT density of bone and bone marrow. The novel
observation of this study is that pretreatment CT density is
associated with the development of PIF.
In our series, 33 of 99 patients (33%) developed PIF after
definitive RT for uterine cervical cancer. Recent studies have
revealed that the postradiation PIF rate is 7–34% [2–8]. The
reported cumulative incidences at two and five years were
10–37% and 8–45%, respectively [1–7]. The current study
showed a relatively higher rate than previous reports, which
we believe is partly because the current study was restricted
to patients who underwent curative RT with HDR-ICBT.
We evaluated both symptomatic and asymptomatic patients,
even though a previous study [11] evaluated only symptom-
atic patients. Furthermore, our study population was relative-
ly older than previous reports [2–5]. The median time
interval between the first day of RT and detection of PIF was
14 months in our study, which is almost equivalent to previ-
ous studies (6–16.9 months) [2–5, 7, 11].
Based on our analysis, a lower CT density of bone and
bone marrow is a significant predisposing factor for develop-
ing postradiation PIF. Although quantitative CT is known to
reflect bone mineral density (BMD) [12], limited evidence
has shown the efficacy of conventional CT density for this
purpose. Nishihara et al. [13] showed that the CT density
obtained from the vertebral body can be used for the estima-
tion of bone mineral content. Link et al. [14] revealed a close
relationship between the CT density obtained from spiral CT
and quantitative CT. We believe our results indicate and
support the close relationship between osteoporosis and post-
radiation PIF that has been noted by some investigators [15].
BMD evaluation is not a routine work-up modality in cer-
vical cancer management. In our series, BMD data were
available for very few patients. Based on our data and previ-
ous studies [13, 14], the conventional CT density obtained
for RT planning may have the potential for predicting the oc-
currence of subsequent PIF. Osteoporosis screening at initial
presentation and appropriate medical intervention may con-
tribute to the reduction of PIF and improve the patient’s
quality of life. Bisphosphonates have been shown to reduce
cancer-induced bone loss effectively and can be a treatment
choice or prophylaxis for postradiation PIF. In fact, bispho-
sphonate use is advocated by some investigators [3, 11].
However, we are cautious about introducing bisphosphonate
use for postradiation PIF prophylaxis because radiation and
bisphosphonates have the same antiangiogenic effects,
which decrease bone turnover [9, 16]. The combined use of
bisphosphonates and radiation may therefore increase the
Fig. 3. Distribution and proportion of PIF in a general
anteroposterior/posteroanterior pelvic field after radiotherapy for
uterine cervical cancer. Fracture lines and bone necrosis within the
irradiated field were counted as PIF.
Postradiation pelvic insufficiency fracture 5
risk of osteonecrosis. Further study is warranted to confirm
the tolerability and efficacy of this approach.
Our study has several limitations. First, this was a single-
institution, retrospective study. The medical records, includ-
ing patients’ symptoms and prescribed medications, may not
be fully accurate. The interval and protocol of imaging
studies were not standardized, causing a detection bias.
Post-treatment MRIs were targeted mainly to the primary
disease, which may have missed fractures of the superior
pelvis and spine. Second, the follow-up period was not long
enough to estimate the true incidence of fracture rate accur-
ately. Third, the evidence correlating CT density and bone
mineral density was limited. Although there are some limita-
tions, this study is the first report showing that the pretreat-
ment CT density of bone and bone marrow is significantly
related to subsequent PIF in patients who have undergone de-
finitive RT for uterine cervical cancer. In addition, the
current study was designed to analyze uniformly treated
patients of uterine cervical cancer who had undergone both
EBRT and ICBT.
Although the sacrum and sacroiliac joint are known to be
the most commonly injured, we have reported a relatively
low rate in the sacroiliac joint. This is because we categorized
as sacral fracture, not sacroiliac fracture, so long as the frac-
ture line involvement to the sacroiliac joint was minimal. It is
difficult to clearly differentiate between sacral fracture and
sacroiliac joint fracture on imaging study. Some previous
studies do not refer to the bone complication in the spine. So
the incidence of sacral and sacroiliac fracture appears to be
relatively low in this study compared with some previous
reports. Ikushima et al. [5] showed that fifth lumbar spinal
fracture occurred in 22% of the cases. The incidence of
lumbar spinal vertebral fracture does not appear to be par-
ticularly high in the current study.
Table 2A. Univariate analysis of risk factors associated with PIF
(n = 99)
Factors P = value HR 95% CI
Age (years) ≥70 0.0010* 3.6 1.64–9.03
<70
BMI ≤21 0.94 1.03 0.49–2.10
>21
Menopausal status Post 0.0013* 1550581 2.83–
Pre
Smoking history Current/past 0.45 0.72 0.26–1.65
never
unknown
Diabetes mellitus + 0.62 1.26 0.47–2.88
−
Rheumatoid arthritis + 0.56 1.58 0.25–5.29
−
Chemotherapy use + 0.057 0.51 0.25–1.02
−
EBRT dose (Gy) ≥50.4 0.48 0.72 0.32–1.93
<50.4
Number of ports 4 0.70 0.85 0.39–2.12
2
RT dosea (α/β = 3) ≥120 0.43 0.78 0.38–1.54
<120
Mean CT density (HU) <35 0.020* 3.09 1.18–9.60
≥35
CT density is listed separately because of a discrepancy in patient
number.
H. Uezono et al.6
Concurrent platinum-based chemotherapy is thought to be
essential in cervical cancer therapy [17]. Although this is
known to increase the toxicity of RT [18], we did not find
evidence that this increased the incidence of fracture. On the
contrary, patients who did not receive chemotherapy tended
to have an increased fracture rate. Likewise, a lower total
dose (WP EBRT plus HDR-ICBT, normalized to BED [α/
β = 3]) was associated with a higher incidence of fracture in
the 99 patients. We assumed that this negative correlation oc-
curred because a more advanced stage of the disease requir-
ing more intensive treatment tended to occur in younger
patients. Because we used different treatment-planning
systems for EBRT and HDR-ICBT, it was impossible to cal-
culate the total dose distribution combining EBRT and
HDR-ICBT. The contribution of the EBRT dose to PIF was
low in this study, which we presume is partly because the
EBRT field did not vary much on a case-by-case basis in
uterine cervical cancer treatment. Although it was not
evident in our study, we assume that there still might be a
correlation between irradiated dose, volume and fracture rate
Table 2B. Univariate analysis of CT density and PIF
(n = 59)
Measured site
CT
density
(HU)
PIF +
(n = 21)
PIF−
(n = 38)
P-value
5th lumbar vertebra ≤130 17 14 0.013
>130 4 24
Right sacrum ≤−35 20 16 0.0033
>−35 1 22
Left sacrum ≤−35 19 19 0.027
>−35 2 19
Mean of the three
sites
<35 16 12 0.020
≥35 5 26
HR = hazard ratio, CI = confidence interval. *P < 0.05. aRT
dose of whole pelvic EBRT and HDR-ICBT normalized to
BED at point A.
Table 3. Multivariate analysis of risk factors associated with
PIF (n = 59)
Factors P-value HR 95% CI
Age (years) 0.31 8.82 0.14–589
Menopause (pre/post) 0.38 191127a 0–
Chemotherapy (+/−) 0.40 0.60 0.18–1.95
Mean CT density (HU) 0.0026* 203 5.84–11582
HR = hazard ratio, CI = confidence interval. *P < 0.05. aNo
event was found in the premenopausal group.
Fig. 4. A follow-up CT image obtained 12 months after treatment
shows multiple sacral fracture lines (arrows).
Table 4: Dose-volume association with PIF
site index PIF + PIF − P-value
Mean ± SE Mean ± SE
Right
pubis
n 7 63
Mean (cGy) 4202.4 ± 133.0 4252.1 ± 44.3 0.64
V50 (%) 32.3 ± 6.4 29.3 ± 2.2 0.33
V40 (%) 64.0 ± 5.0 68.7 ± 1.7 0.81
V30 (%) 86.0 ± 3.7 87.7 ± 1.2 0.66
V20 (%) 96.7 ± 1.8 96.9 ± 0.6 0.54
Left
pubis
n 7 63
Mean (cGy) 4121.4 ± 125.7 4293.4 ± 41.9 0.90
V50 (%) 20.00 ± 6.7 31.7 ± 2.2 0.95
V40 (%) 64.0 ± 5.0 69.9 ± 1.7 0.87
V30 (%) 85.0 ± 3.2 88.5 ± 1.1 0.85
V20 (%) 95.7 ± 1.2 97.4 ± 0.4 0.89
Sacrum n 9 61
Mean (cGy) 4585.0 ± 98.0 4599.3 ± 37.7 0.89
V50 (%) 43.9 ± 6.9 40.1 ± 2.7 0.30
V40 (%) 81.2 ± 3.7 82.7 ± 1.4 0.64
V30 (%) 95.4 ± 1.6 96.8 ± 0.6 0.45
V20 (%) 99.9 ± 0.6 99.6 ± 0.2 0.31
L5 n 11 59
Mean (cGy) 4226.6 ± 264.4 4045.1 ± 114.1 0.27
V50 (%) 14.9 ± 5.3 19.2 ± 2.3 0.77
V40 (%) 58.0 ± 7.8 59.2 ± 3.4 0.89
V30 (%) 96.6 ± 6.9 88.8 ± 3.0 0.15
V20 (%) 99.5 ± 5.8 92.5 ± 2.5 0.14
SE = standard error.
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[19]. Rubin noted that the risk of radiation damage to an
organ is generally proportional to the dose and volume irra-
diated. IMRT will be a promising option for dose reduction
to bones as it is studied as an option for lessening hemato-
logic toxicity [20, 21]. Further studies are required to
confirm this assumption.
The dose-volume analysis in the current study suggests
that the HDR-ICBT dose contributes to pubic fracture, al-
though this was not statistically significant. Tai et al. and Fu
et al. reported that 5–20% of prescribed brachytherapy doses
affect the pubic bone [11, 22]. Analyzing a patient population
with postoperative RT who have not received HDR-ICBT
may provide the additional data required to ascertain the
effect of HDR-ICBT.
CONCLUSION
In conclusion, PIF after definitive RT for uterine cervical
cancer developed in 33% of patients. The estimated 2- and
5-year prevalence rates were 32% and 63%, respectively.
Statistical analysis revealed that older age, postmenopausal
state, and decreased CT density of bone and bone marrow
were the predisposing risk factors.
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